HRP20040360B1 - Linearni baziäśni spojevi koji djeluju kao antagonisti nk2 i njihove formulacije - Google Patents

Linearni baziäśni spojevi koji djeluju kao antagonisti nk2 i njihove formulacije

Info

Publication number
HRP20040360B1
HRP20040360B1 HRP20040360AA HRP20040360A HRP20040360B1 HR P20040360 B1 HRP20040360 B1 HR P20040360B1 HR P20040360A A HRP20040360A A HR P20040360AA HR P20040360 A HRP20040360 A HR P20040360A HR P20040360 B1 HRP20040360 B1 HR P20040360B1
Authority
HR
Croatia
Prior art keywords
formulations
antagonist activity
basic compounds
linear basic
linear
Prior art date
Application number
HRP20040360AA
Other languages
English (en)
Inventor
Alessandro Sisto
Valerio Caciagli
Maria Altamura
Alessandro Giolitti
Valentina Fedi
Antonio Guidi
Danilo Giannotti
Nicholas Harmat
Rossano Nannicini
Franco Pasqui
Carlo Alberto Maggi
Original Assignee
Malesci Istituto Farmacobiologico S. P. A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITFI20010203 external-priority patent/ITFI20010203A1/it
Priority claimed from ITFI20020104 external-priority patent/ITFI20020104A1/it
Application filed by Malesci Istituto Farmacobiologico S. P. A. filed Critical Malesci Istituto Farmacobiologico S. P. A.
Publication of HRP20040360A2 publication Critical patent/HRP20040360A2/hr
Publication of HRP20040360B1 publication Critical patent/HRP20040360B1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Ovdje su opisani spojevi formule (I) korisni kao antagonisti tahikinina općenito, a posebno neurokinina A i farmaceutske formulacije koje sadrže spojeve formule (I).
HRP20040360AA 2001-10-29 2004-04-21 Linearni baziäśni spojevi koji djeluju kao antagonisti nk2 i njihove formulacije HRP20040360B1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITFI20010203 ITFI20010203A1 (it) 2001-10-29 2001-10-29 Composti lineari con caratteristiche basiche ad attivita' nk-2 antagonista,loro processi di sintesi e formulazioni che li contengono
ITFI20020104 ITFI20020104A1 (it) 2002-06-14 2002-06-14 Composti lineari con caratteristiche basiche ed attivita' nk-2 antagonista, loro processi di sintesi e formulazioni che li contengono
PCT/EP2002/012022 WO2003037916A2 (en) 2001-10-29 2002-10-28 Linear basic compounds having nk-2 antagonist activity and formulations thereof

Publications (2)

Publication Number Publication Date
HRP20040360A2 HRP20040360A2 (en) 2004-08-31
HRP20040360B1 true HRP20040360B1 (hr) 2013-02-28

Family

ID=26332714

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20040360AA HRP20040360B1 (hr) 2001-10-29 2004-04-21 Linearni baziäśni spojevi koji djeluju kao antagonisti nk2 i njihove formulacije

Country Status (37)

Country Link
US (1) US7273856B2 (hr)
EP (1) EP1442050B1 (hr)
JP (1) JP4511835B2 (hr)
KR (1) KR100958226B1 (hr)
CN (1) CN100413882C (hr)
AR (1) AR037044A1 (hr)
AT (1) ATE339439T1 (hr)
AU (1) AU2002351794B2 (hr)
BR (2) BRPI0213574B1 (hr)
CA (1) CA2464353C (hr)
CO (1) CO5580834A2 (hr)
CY (1) CY1105847T1 (hr)
DE (1) DE60214750T2 (hr)
DK (1) DK1442050T3 (hr)
EA (1) EA007855B1 (hr)
EG (1) EG24335A (hr)
ES (1) ES2272792T3 (hr)
HK (1) HK1063326A1 (hr)
HR (1) HRP20040360B1 (hr)
HU (1) HUP0402081A3 (hr)
IL (1) IL161649A0 (hr)
MX (1) MXPA04003974A (hr)
MY (1) MY130373A (hr)
NO (1) NO331227B1 (hr)
NZ (1) NZ533097A (hr)
PA (1) PA8557201A1 (hr)
PE (1) PE20030611A1 (hr)
PL (1) PL209411B1 (hr)
PT (1) PT1442050E (hr)
RS (1) RS52290B (hr)
SI (1) SI1442050T1 (hr)
SV (1) SV2004001370A (hr)
TN (1) TNSN04077A1 (hr)
UA (1) UA78975C2 (hr)
UY (1) UY27514A1 (hr)
WO (1) WO2003037916A2 (hr)
ZA (1) ZA200404163B (hr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06013213A (es) * 2004-05-13 2007-02-08 Boehringer Ingelheim Int Nuevas amidas sustituidas del acido tiofencarboxilico, su obtencion y su uso como medicamentos.
ITFI20040221A1 (it) * 2004-10-27 2005-01-27 Guidotti & C Spa Composizioni farmaceutiche a base di nk2 antagonisti per uso pediatrico
JP4012239B2 (ja) * 2006-01-11 2007-11-21 生化学工業株式会社 オキサゾロン誘導体
US20080227823A1 (en) * 2007-03-12 2008-09-18 Hassan Pajouhesh Amide derivatives as calcium channel blockers
IT1394304B1 (it) * 2009-05-21 2012-06-06 Malesci Sas Processo per la preparazione di ibodutant (men15596) e relativi intermedi
JP5929483B2 (ja) 2011-05-10 2016-06-08 住友化学株式会社 植物の生長を促進する方法
EP2723718A1 (en) 2011-06-24 2014-04-30 Amgen Inc. Trpm8 antagonists and their use in treatments
PE20140868A1 (es) 2011-06-24 2014-07-18 Amgen Inc Antagonistas trpm8 y su uso en tratamientos
EP2671575A1 (en) * 2012-06-04 2013-12-11 Universität Regensburg Ras inhibitors
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
AU2022292554A1 (en) 2021-06-14 2024-01-04 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019966A1 (en) * 1994-01-19 1995-07-27 A. Menarini Industrie Farmaceutiche Riunite S.R.L. Tachykinins antagonists
WO2000014109A1 (en) * 1998-09-08 2000-03-16 Menarini Ricerche S.P.A. Basic products having antagonistic activity on the nk-1 receptor and their use in pharmaceutical compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3711335A1 (de) * 1987-04-03 1988-10-20 Merck Patent Gmbh Aminosaeurederivate
US5164372A (en) 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
PT655055E (pt) 1992-08-13 2001-03-30 Warner Lambert Co Antagonistas de taquiquinina
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
PT764163E (pt) * 1994-06-06 2002-03-28 Warner Lambert Co Antagonistas do receptor de taquiquinina (nk1)
US5483070A (en) * 1994-08-02 1996-01-09 Packard Instrument Company Scintillation counter
IT1291776B1 (it) 1997-02-07 1999-01-21 Menarini Ricerche Spa Composti monociclici a quattro residui bifunzionali, aventi azione nk-2 antagonista
IT1291823B1 (it) 1997-04-08 1999-01-21 Menarini Ricerche Spa Composti pseudo-peptidici, loro preparazione ed uso in formulazioni farmaceutiche
PL337672A1 (en) * 1997-06-30 2000-08-28 Nippon Kayaku Kk Novel derivatives of naphtyridine or their salts
US6262069B1 (en) * 1997-08-29 2001-07-17 Protherics Molecular Design Limited 1-amino-7-isoquinoline derivatives as serine protease inhibitors
US6740682B2 (en) * 1997-08-29 2004-05-25 Tularik Limited Meta-benzamidine derivatives as serine protease inhibitors
AU5414000A (en) * 1999-06-14 2001-01-02 Eli Lilly And Company Compounds
IT1307809B1 (it) 1999-10-21 2001-11-19 Menarini Ricerche Spa Composti monociclici basici ad azione nk-2 antagonista, processi difabbricazione e formulazioni che li contengono.
GB0030305D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030303D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
US20050038692A1 (en) 2003-08-14 2005-02-17 Kane John Michael System and method for facilitating centralized candidate selection and monitoring subject participation in clinical trial studies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019966A1 (en) * 1994-01-19 1995-07-27 A. Menarini Industrie Farmaceutiche Riunite S.R.L. Tachykinins antagonists
WO2000014109A1 (en) * 1998-09-08 2000-03-16 Menarini Ricerche S.P.A. Basic products having antagonistic activity on the nk-1 receptor and their use in pharmaceutical compositions

Also Published As

Publication number Publication date
SV2004001370A (es) 2004-02-19
HUP0402081A2 (hu) 2005-02-28
AR037044A1 (es) 2004-10-20
NO20042083L (no) 2004-05-21
CY1105847T1 (el) 2011-02-02
PL209411B1 (pl) 2011-08-31
WO2003037916A3 (en) 2004-02-12
ES2272792T3 (es) 2007-05-01
TNSN04077A1 (en) 2006-06-01
MY130373A (en) 2007-06-29
US7273856B2 (en) 2007-09-25
PA8557201A1 (es) 2003-06-30
NO331227B1 (no) 2011-11-07
EA007855B1 (ru) 2007-02-27
ATE339439T1 (de) 2006-10-15
RS36504A (en) 2007-04-10
CN100413882C (zh) 2008-08-27
NZ533097A (en) 2005-07-29
WO2003037916A2 (en) 2003-05-08
EA200400588A1 (ru) 2004-08-26
EP1442050B1 (en) 2006-09-13
UY27514A1 (es) 2003-06-30
HRP20040360A2 (en) 2004-08-31
DK1442050T3 (da) 2007-01-08
CA2464353C (en) 2013-05-28
AU2002351794A2 (en) 2003-05-12
BR0213574A (pt) 2004-10-26
CN1578786A (zh) 2005-02-09
MXPA04003974A (es) 2005-01-25
KR100958226B1 (ko) 2010-05-17
ZA200404163B (en) 2006-01-25
PL368824A1 (en) 2005-04-04
CO5580834A2 (es) 2005-11-30
PE20030611A1 (es) 2003-09-02
HUP0402081A3 (en) 2007-05-29
EG24335A (en) 2009-02-01
EP1442050A2 (en) 2004-08-04
HK1063326A1 (en) 2004-12-24
US20040259930A1 (en) 2004-12-23
DE60214750D1 (de) 2006-10-26
AU2002351794B2 (en) 2008-09-11
RS52290B (en) 2012-10-31
IL161649A0 (en) 2004-09-27
KR20050040815A (ko) 2005-05-03
UA78975C2 (en) 2007-05-10
PT1442050E (pt) 2007-01-31
CA2464353A1 (en) 2003-05-08
JP2005521638A (ja) 2005-07-21
BRPI0213574B1 (pt) 2018-04-10
DE60214750T2 (de) 2007-09-13
JP4511835B2 (ja) 2010-07-28
SI1442050T1 (sl) 2007-04-30

Similar Documents

Publication Publication Date Title
CY1105847T1 (el) Γραμμικες βασικες ενωσεις που εμφανιζουν δραστικοτητα ανταγωνιστη της nk-2 και σκευασματα αυτων
NO20062677L (no) Benzyleteraminforbindelser anvendbare som CCR-5-antagonister
BG66085B1 (bg) Фенилаланинови производни
CO5590918A2 (es) Formulaciones
PT1506185E (pt) Compostos novos e sua utilizacao
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
EA200400467A1 (ru) Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора
EA200400280A1 (ru) Новые неочищенные и кристаллические формы гидрохлорида лерканидипина
ATE383345T1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
DE602004031410D1 (de) Inden derivate als pharmazeutika
ATE253359T1 (de) Antithrombotische mittel
TR200503401T1 (tr) Kuetiapin (Quetiapine) Fumarat'ın yeni polimorfları
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
DE69828522D1 (de) Antithrombotische mittel
ATE308513T1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
NO20030509L (no) Nye N-(2-fenyl-3-aminopropyl)naftamider
DE60322110D1 (de) Substituierte 4-(4-piperidin-yl-piperazin-1-yl)-azntagonisten
SE0301371D0 (sv) New Compounds
DK1631574T3 (da) Colchicosidanaloge
SE0403117D0 (sv) New compounds 1
ATE298564T1 (de) Arzneimittelformulierung enthaltend einen ltb4 antagonisten und einen netzmittel
ATE374751T1 (de) 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern
ATE364594T1 (de) (4-acylaminopiperidin-1-yl)acetamide als neurokininantagonisten
MXPA05011430A (es) Compuestos lineares basicos antagonistas de nk-2 y formulaciones que los contienen.
ITMI20020639A1 (it) Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20170922

Year of fee payment: 16

PBON Lapse due to non-payment of renewal fee

Effective date: 20181028